The Differentially Expressed Genes Responsible for the Development of T Helper 9 Cells From T Helper 2 Cells in Various Disease States: Immuno-Interactomics Study (Preprint)
Authors: Khokhar Manoj , Purohit Purvi , Gadwal Ashita , Tomo Sojit , Bajpai Nitin Kumar , Shukla Ravindra 
Published: February 2023

BACKGROUND

T helper (Th) 9 cells are a novel subset of Th cells that develop independently from Th2 cells and are characterized by the secretion of interleukin (IL)-9. Studies have suggested the involvement of Th9 cells in variable diseases such as allergic and pulmonary diseases (eg, asthma, chronic obstructive airway disease, chronic rhinosinusitis, nasal polyps, and pulmonary hypoplasia), metabolic diseases (eg, acute leukemia, myelocytic leukemia, breast cancer, lung cancer, melanoma, pancreatic cancer), neuropsychiatric disorders (eg, Alzheimer disease), autoimmune diseases (eg, Graves disease, Crohn disease, colitis, psoriasis, systemic lupus erythematosus, systemic scleroderma, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, atopic dermatitis, eczema), and infectious diseases (eg, tuberculosis, hepatitis). However, there is a dearth of information on its involvement in other metabolic, neuropsychiatric, and infectious diseases.

OBJECTIVE

This study aims to identify significant differentially altered genes in the conversion of Th2 to Th9 cells, and their regulating microRNAs (miRs) from publicly available Gene Expression Omnibus data sets of the mouse model using in silico analysis to unravel various pathogenic pathways involved in disease processes.

METHODS

Using differentially expressed genes (DEGs) identified from 2 publicly available data sets (GSE99166 and GSE123501) we performed functional enrichment and network analyses to identify pathways, protein-protein interactions, miR-messenger RNA associations, and disease-gene associations related to significant differentially altered genes implicated in the conversion of Th2 to Th9 cells.

RESULTS

We extracted 260 common downregulated, 236 common upregulated, and 634 common DEGs from the expression profiles of data sets GSE99166 and GSE123501. Codifferentially expressed ILs, cytokines, receptors, and transcription factors (TFs) were enriched in 7 crucial Kyoto Encyclopedia of Genes and Genomes pathways and Gene Ontology. We constructed the protein-protein interaction network and predicted the top regulatory miRs involved in the Th2 to Th9 differentiation pathways. We also identified various metabolic, allergic and pulmonary, neuropsychiatric, autoimmune, and infectious diseases as well as carcinomas where the differentiation of Th2 to Th9 may play a crucial role.

CONCLUSIONS

This study identified hitherto unexplored possible associations between Th9 and disease states. Some important ILs, including <i>CCL1</i> (chemokine [C-C motif] ligand 1), <i>CCL20</i> (chemokine [C-C motif] ligand 20), <i>IL-13</i>, <i>IL-4</i>, <i>IL-12A</i>, and <i>IL-9</i>; receptors, including <i>IL-12RB1</i>, <i>IL-4RA</i> (interleukin 9 receptor alpha), <i>CD53</i> (cluster of differentiation 53), <i>CD6</i> (cluster of differentiation 6), <i>CD5</i> (cluster of differentiation 5), <i>CD83</i> (cluster of differentiation 83), <i>CD197</i> (cluster of differentiation 197), <i>IL-1RL1</i> (interleukin 1 receptor-like 1), <i>CD101</i> (cluster of differentiation 101), <i>CD96</i> (cluster of differentiation 96), <i>CD72</i> (cluster of differentiation 72), <i>CD7</i> (cluster of differentiation 7), <i>CD152</i> (cytotoxic T lymphocyte–associated protein 4), <i>CD38</i> (cluster of differentiation 38), <i>CX3CR1</i> (chemokine [C-X3-C motif] receptor 1), <i>CTLA2A</i> (cytotoxic T lymphocyte–associated protein 2 alpha), <i>CTLA28</i>, and <i>CD196</i> (cluster of differentiation 196); and TFs, including <i>FOXP3</i> (forkhead box P3), <i>IRF8</i> (interferon regulatory factor 8), <i>FOXP2</i> (forkhead box P2), <i>RORA</i> (RAR-related orphan receptor alpha), <i>AHR</i> (aryl-hydrocarbon receptor), <i>MAF</i> (avian musculoaponeurotic fibrosarcoma oncogene homolog), <i>SMAD6</i> (SMAD family member 6), <i>JUN</i> (Jun proto-oncogene), <i>JAK2</i> (Janus kinase 2), <i>EP300</i> (E1A binding protein p300), <i>ATF6</i> (activating transcription factor 6), <i>BTAF1</i> (B-TFIID TATA-box binding protein associated factor 1), <i>BAFT</i> (basic leucine zipper transcription factor), <i>NOTCH1</i> (neurogenic locus notch homolog protein 1), <i>GATA3</i> (GATA binding protein 3), <i>SATB1</i> (special AT-rich sequence binding protein 1), <i>BMP7</i> (bone morphogenetic protein 7), and <i>PPARG</i> (peroxisome proliferator–activated receptor gamma, were able to identify significant differentially altered genes in the conversion of Th2 to Th9 cells. We identified some common miRs that could target the DEGs. The scarcity of studies on the role of Th9 in metabolic diseases highlights the lacunae in this field. Our study provides the rationale for exploring the role of Th9 in various metabolic disorders such as diabetes mellitus, diabetic nephropathy, hypertensive disease, ischemic stroke, steatohepatitis, liver fibrosis, obesity, adenocarcinoma, glioblastoma and glioma, malignant neoplasm of stomach, melanoma, neuroblastoma, osteosarcoma, pancreatic carcinoma, prostate carcinoma, and stomach carcinoma.